sub:assertion {
  <http://purl.obolibrary.org/obo/MONDO_0008114> a biolink:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/MONDO_0008114> ;
    rdf:predicate biolink:treats ;
    rdf:subject <https://identifiers.org/DRUGBANK:DB01175> ;
    a rdf:Statement ;
    rdfs:label "Escitalopram showed favorable pharmacokinetics and good tolerability. It is the most 5-HT-selective among SSRIs, with little or no affinity for other transmitter transporters or receptors [59]. Compared to other SSRIs, escitalopram may have weak or minimal interactions with the cytochrome P450 system [60, 61]. In a randomized, double-blind, placebo-controlled 24-week trial in OCD, escitalopram (20 mg/day) was associated with an increase in response rate compared to placebo after 12 weeks. Other placebo-controlled studies consistently showed escitalopram-related treatment response [25, 30]. 20 mg/day escitalopram has also been associated with better OCD symptom remission compared to 40 mg/day paroxetine or placebo at week 12 [30]. Three different escitalopram dosages (5, 10, and 20 mg/day) were compared with a fixed, 20 mg/day dose of paroxetine in a 12-week study, in which escitalopram showed both greater efficacy and better tolerability [62]." ;
    biolink:has_population_context sub:context ;
    biolink:provided_by <https://w3id.org/um/NeuroDKG> ;
    biolink:publications <https://pubmed.ncbi.nlm.nih.gov/30101713> ;
    biolink:relation <https://w3id.org/um/neurodkg/OffLabelIndication> .
  sub:context a biolink:Cohort ;
    rdfs:label "adults" .
  <https://identifiers.org/DRUGBANK:DB01175> a biolink:Drug .
}